ZEHRA SUCUOĞLU İŞLEYEN, MEHMET BEŞİROĞLU, MELİH ŞİMŞEK, AYŞE İREM YASİN, ATAKAN TOPÇU, ADEM AKÇAKAYA, MESUT SEKER, HACI MEHMET TÜRK
Eurasian Journal of Medical Investigation - 2024;8(2):113-118
Objectives: We aimed to evaluate the relation of the pre-treatment hemoglobin-albumin-lymphocyte-platelet (HALP) score with survival and prognosis of locally advanced esophageal squamous cell carcinoma (ESCC) patients receiving chemoradiotherapy (CRT). Methods: We retrospectively included 45 patients with esophageal squamous cell carcinoma who were treated with chemoradiotherapy. The HALP score was calculated as hemoglobin level (g/L)*albumin level (g/L)*lymphocyte count (/L)/platelet count(/L). Results: According to the receiver operating characteristic (ROC) curve, the median of the HALP score was 42.36. Ac cording to this value, the patients were divided into two groups; Group 1 included 28 patients who had a HALP score <42.36 and Group 2 included 17 patients who had a HALP score >42.36. Median OS was 20.5 months in Group 1 and the median OS was not reached in Group 2 (p=0.033). Median PFS in all patient groups was 15.2 months. The median PFS was 12.2 months in Group 1 and 30.9 months in Group 2 (p=0.127). Univariate Cox regression analysis showed that pre-treatment low levels of HALP were associated with a short median time of OS (p=0.042). Conclusion: Our study suggested that pretreatment low HALP score was associated with poor OS in patients with lo cally advanced ESCC who were treated with CRT.
